JP2024537779A5 - - Google Patents
Info
- Publication number
- JP2024537779A5 JP2024537779A5 JP2024519378A JP2024519378A JP2024537779A5 JP 2024537779 A5 JP2024537779 A5 JP 2024537779A5 JP 2024519378 A JP2024519378 A JP 2024519378A JP 2024519378 A JP2024519378 A JP 2024519378A JP 2024537779 A5 JP2024537779 A5 JP 2024537779A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- amino acid
- binding site
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163250160P | 2021-09-29 | 2021-09-29 | |
| US63/250,160 | 2021-09-29 | ||
| PCT/US2022/077083 WO2023056252A1 (en) | 2021-09-29 | 2022-09-27 | Proteins binding nkg2d, cd16 and baff-r |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024537779A JP2024537779A (ja) | 2024-10-16 |
| JP2024537779A5 true JP2024537779A5 (enExample) | 2025-10-07 |
Family
ID=85780907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024519378A Pending JP2024537779A (ja) | 2021-09-29 | 2022-09-27 | Ｎｋｇ２ｄ、ｃｄ１６及びｂａｆｆ－ｒに結合するタンパク質 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20240270861A1 (enExample) |
| EP (1) | EP4408896A4 (enExample) |
| JP (1) | JP2024537779A (enExample) |
| KR (1) | KR20240087855A (enExample) |
| CN (1) | CN118317978A (enExample) |
| AR (1) | AR127162A1 (enExample) |
| AU (1) | AU2022358500A1 (enExample) |
| CA (1) | CA3233377A1 (enExample) |
| CL (1) | CL2024000922A1 (enExample) |
| CO (1) | CO2024003967A2 (enExample) |
| IL (1) | IL311617A (enExample) |
| MX (1) | MX2024003993A (enExample) |
| PE (1) | PE20241584A1 (enExample) |
| TW (1) | TW202330603A (enExample) |
| WO (1) | WO2023056252A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| CA3090244A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| CN112119093A (zh) | 2018-02-20 | 2020-12-22 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 |
| CA3108427A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| CN113164570B (zh) | 2018-08-08 | 2024-05-14 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| AU2021268340A1 (en) | 2020-05-06 | 2022-12-08 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012076670A2 (en) * | 2010-12-10 | 2012-06-14 | Novartis Ag | Antibody formulation |
| PL3151921T3 (pl) * | 2014-06-06 | 2020-02-28 | Bristol-Myers Squibb Company | Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania |
| TWI717375B (zh) * | 2015-07-31 | 2021-02-01 | 德商安美基研究（慕尼黑）公司 | Ｃｄ７０及ｃｄ３抗體構築體 |
| EP4273258A3 (en) * | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| CA3064567A1 (en) * | 2017-05-23 | 2018-11-29 | Dragonfly Therapeutics, Inc. | A protein binding nkg2d, cd16 and a tumor-associated antigen |
| RU2021110369A (ru) * | 2017-09-07 | 2021-06-01 | Драгонфлай Терапьютикс, Инк. | Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген |
| EA202091976A1 (ru) * | 2018-02-20 | 2021-07-06 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на cd33, и их применение |
| CA3108427A1 (en) * | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| BR112022007128A2 (pt) * | 2019-10-15 | 2022-07-05 | Dragonfly Therapeutics Inc | Ligação de proteínas nkg2d, cd16 e flt3 |
| WO2021108661A2 (en) * | 2019-11-26 | 2021-06-03 | Novartis Ag | Chimeric antigen receptors and uses thereof |
-
2022
- 2022-09-27 JP JP2024519378A patent/JP2024537779A/ja active Pending
- 2022-09-27 IL IL311617A patent/IL311617A/en unknown
- 2022-09-27 KR KR1020247013645A patent/KR20240087855A/ko active Pending
- 2022-09-27 CN CN202280064771.XA patent/CN118317978A/zh active Pending
- 2022-09-27 WO PCT/US2022/077083 patent/WO2023056252A1/en not_active Ceased
- 2022-09-27 TW TW111136528A patent/TW202330603A/zh unknown
- 2022-09-27 AU AU2022358500A patent/AU2022358500A1/en active Pending
- 2022-09-27 PE PE2024000614A patent/PE20241584A1/es unknown
- 2022-09-27 AR ARP220102597A patent/AR127162A1/es unknown
- 2022-09-27 CA CA3233377A patent/CA3233377A1/en active Pending
- 2022-09-27 MX MX2024003993A patent/MX2024003993A/es unknown
- 2022-09-27 EP EP22877499.8A patent/EP4408896A4/en active Pending
-
2024
- 2024-03-27 CO CONC2024/0003967A patent/CO2024003967A2/es unknown
- 2024-03-27 CL CL2024000922A patent/CL2024000922A1/es unknown
- 2024-03-28 US US18/620,824 patent/US20240270861A1/en not_active Abandoned
- 2024-03-29 US US18/622,766 patent/US20240360223A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022551969A5 (enExample) | ||
| US20230227581A1 (en) | Heterodimeric antibodies that bind enpp3 and cd3 | |
| CN114341186B (zh) | 双特异性抗LRRC15和CD3ε抗体 | |
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP6669722B2 (ja) | Ｃｄ３結合ドメイン | |
| JP2021098732A5 (enExample) | ||
| JP2021098733A5 (enExample) | ||
| JP2021533169A5 (enExample) | ||
| IL311617A (en) | NKG2D, CD16 and BAFF-R binding proteins | |
| JP2020533311A5 (ja) | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 | |
| RU2019123613A (ru) | Биспецифические антигенсвязывающие молекулы, содержащие антитело к4-1вв, клон 20н4.9 | |
| Xiong et al. | Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20× anti-CD3 bispecific diabody | |
| CN117157319A (zh) | 结合cd3和cldn6的异二聚抗体 | |
| JP2021533159A5 (enExample) | ||
| JP2023532129A5 (enExample) | ||
| RU2019108429A (ru) | Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения | |
| IL292780A (en) | A new 4-1bbl trimer containing antigen-binding molecules | |
| JP2023516004A5 (enExample) | ||
| JP2023548529A5 (enExample) | ||
| US20240059786A1 (en) | Anti-cd28 x anti-trop2 antibodies | |
| JP2023511376A5 (enExample) | ||
| US20230340128A1 (en) | Anti-cd28 x anti-msln antibodies | |
| US20240417466A1 (en) | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 | |
| US20230018670A1 (en) | Bispecific GD2 and B7H3 Binding Molecules and Methods of Use | |
| JP2023547506A5 (enExample) |